Psychiatry

Tardive Dyskinesia

Expert Roundtables Podcast: Employing Evidence-Based Management Strategies for Tardive Dyskinesia

expert roundtables by Christoph U. Correll, MD; Andrew J. Cutler, MD; Rakesh Jain, MD, MPH

Overview

Tardive dyskinesia (TD) is a feared and often undertreated condition despite the availability of 2 US Food and Drug Administration (FDA)–approved treatments. In this discussion, our featured experts explore the challenges in recognizing and managing TD, emphasizing the importance of psychoeducation, early intervention, and sticking to the use of FDA-approved VMAT2 inhibitors.

References

American Psychiatric Association, ed. The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia. 3rd ed. American Psychiatric Association Publishing; 2021. Accessed November 19, 2024. https://psychiatryonline.org/doi/book/10.1176/appi.books.9780890424841#toc__book__section

Arya D, Khan T, Margolius AJ, Fernandez HH. Tardive dyskinesia: treatment update. Curr Neurol Neurosci Rep. 2019;19(9):69. doi:10.1007/s11910-019-0976-1

Atlas SJ, Agboola F, Curfman G. Effectiveness and value of 2 novel treatments for tardive dyskinesia. JAMA Intern Med. 2018;178(8):1110-1112. doi:10.1001/jamainternmed.2018.2463

Carbon M, Kane JM, Leucht S, Correll CU. Tardive dyskinesia risk with first- and second-generation antipsychotics in comparative randomized controlled trials: a meta-analysis. World Psychiatry. 2018;17(3):330-340. doi:10.1002/wps.20579

Caroff SN. A new era in the diagnosis and treatment of tardive dyskinesia. CNS Spectr. 2023;28(4):401-415. doi:10.1017/S1092852922000992

Caroff SN, Citrome L, Meyer J, et al. A modified Delphi consensus study of the screening, diagnosis, and treatment of tardive dyskinesia. J Clin Psychiatry. 2020;81(2):19cs12983. doi:10.4088/JCP.19cs12983

Jain R, Ayyagari R, Goldschmidt D, Zhou M, Finkbeiner S, Leo S. Impact of tardive dyskinesia on patients and caregivers: a survey of caregivers in the United States. J Patient Rep Outcomes. 2023;7(1):122. Published correction appears in J Patient Rep Outcomes. 2024;8(1):51.

Jain R, Correll CU. Tardive dyskinesia: recognition, patient assessment, and differential diagnosis. J Clin Psychiatry. 2018;79(2):nu17034ah1c. doi:10.4088/JCP.nu17034ah1c

Owens DC. Tardive dyskinesia update: treatment and management. BJPsych Adv. 2019;25(2):78-89. doi:10.1192/bja.2018.46

Ricciardi L, Pringsheim T, Barnes TRE, et al. Treatment recommendations for tardive dyskinesia. Can J Psychiatry. 2019;64(6):388-399. doi:10.1177/0706743719828968

Profile

Christoph U. Correll, MD

Professor, Departments of Psychiatry and Molecular Medicine

Donald and Barbara Zucker School of Medicine at Hofstra/Northwell

Hempstead, NY

Professor and Chair, Department of Child and Adolescent Psychiatry

Charité - University Medicine Berlin

Berlin, Germany

Profile

Andrew J. Cutler, MD

Clinical Associate Professor of Psychiatry
SUNY Upstate Medical University
Lakewood Ranch, FL
Chief Medical Officer
Neuroscience Education Institute
Carlsbad, CA